The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

This has put the company in direct competition with RSV vaccines Arexvy and Abrysvo, which are marketed by pharma giants GSK and Pfizer, respectively. As a result, management expects to record ...

Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At ...

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

Two other RSV vaccines – GSK's Arexvy and Moderna's mResvia – are approved for older adult use only. Abrysvo made $890 million in sales last year, but it's not clear what proportion of that ...

The new prefilled syringe has the same composition but removes the need for reconstitution, providing a more convenient option for health care providers who administer vaccines. According to the ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Shares were also aided by a successful US and European launch of Arexvy, a respiratory syncytial virus (RSV) vaccine for older adults. Although risks around the Zantac litigation remain a concern ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Pregnant women across Australia will be offered a free vaccine to protect their babies against respiratory syncytial virus (RSV) from next month. The government's $174.5 million investment will ...